AtriCure Statistics
Total Valuation
AtriCure has a market cap or net worth of $1.08 billion. The enterprise value is $1.05 billion.
| Market Cap | 1.08B |
| Enterprise Value | 1.05B |
Important Dates
The next estimated earnings date is Tuesday, July 23, 2024, after market close.
| Earnings Date | Jul 23, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AtriCure has 48.38 million shares outstanding. The number of shares has increased by 1.33% in one year.
| Shares Outstanding | 48.38M |
| Shares Change (YoY) | +1.33% |
| Shares Change (QoQ) | +0.58% |
| Owned by Insiders (%) | 3.21% |
| Owned by Institutions (%) | 104.84% |
| Float | 46.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.61 |
| Forward PS | 2.23 |
| PB Ratio | 2.37 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.00, with a Debt / Equity ratio of 0.17.
| Current Ratio | 4.00 |
| Quick Ratio | 2.63 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.24 |
Financial Efficiency
Return on equity (ROE) is -8.10% and return on invested capital (ROIC) is -5.98%.
| Return on Equity (ROE) | -8.10% |
| Return on Assets (ROA) | -6.20% |
| Return on Capital (ROIC) | -5.98% |
| Revenue Per Employee | $394,859 |
| Profits Per Employee | -$35,458 |
| Employee Count | 1,050 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 1.70 |
Taxes
In the past 12 months, AtriCure has paid $696,000 in taxes.
| Income Tax | 696,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.23% in the last 52 weeks. The beta is 1.42, so AtriCure's price volatility has been higher than the market average.
| Beta (5Y) | 1.42 |
| 52-Week Price Change | -54.23% |
| 50-Day Moving Average | 22.37 |
| 200-Day Moving Average | 31.78 |
| Relative Strength Index (RSI) | 50.00 |
| Average Volume (20 Days) | 975,406 |
Short Selling Information
The latest short interest is 3.30 million, so 6.82% of the outstanding shares have been sold short.
| Short Interest | 3.30M |
| Short Previous Month | 3.53M |
| Short % of Shares Out | 6.82% |
| Short % of Float | 7.07% |
| Short Ratio (days to cover) | 5.83 |
Income Statement
In the last 12 months, AtriCure had revenue of $414.60 million and -$37.23 million in losses. Loss per share was -$0.80.
| Revenue | 414.60M |
| Gross Profit | 312.03M |
| Operating Income | -31.82M |
| Pretax Income | -36.54M |
| Net Income | -37.23M |
| EBITDA | -13.25M |
| EBIT | -29.57M |
| Loss Per Share | -$0.80 |
Balance Sheet
The company has $105.96 million in cash and $75.36 million in debt, giving a net cash position of $30.59 million or $0.63 per share.
| Cash & Cash Equivalents | 105.96M |
| Total Debt | 75.36M |
| Net Cash | 30.59M |
| Net Cash Per Share | $0.63 |
| Equity (Book Value) | 456.31M |
| Book Value Per Share | 9.43 |
| Working Capital | 183.97M |
Cash Flow
In the last 12 months, operating cash flow was -$12.45 million and capital expenditures -$42.27 million, giving a free cash flow of -$54.72 million.
| Operating Cash Flow | -12.45M |
| Capital Expenditures | -42.27M |
| Free Cash Flow | -54.72M |
| FCF Per Share | -$1.17 |
Margins
Gross margin is 75.26%, with operating and profit margins of -7.67% and -8.98%.
| Gross Margin | 75.26% |
| Operating Margin | -7.67% |
| Pretax Margin | -8.81% |
| Profit Margin | -8.98% |
| EBITDA Margin | -3.20% |
| EBIT Margin | -7.13% |
| FCF Margin | -13.20% |
Dividends & Yields
AtriCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.33% |
| Shareholder Yield | -1.33% |
| Earnings Yield | -3.44% |
| FCF Yield | -5.05% |
Analyst Forecast
The average price target for AtriCure is $45.00, which is 100.98% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $45.00 |
| Price Target Difference | 100.98% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 17.07% |
| EPS Growth Forecast (5Y) | -10.24% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AtriCure has an Altman Z-Score of 4.84 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.84 |
| Piotroski F-Score | 4 |